Introduction
After over 27 years, it is important to pause and consider the devastating extent of the HIV pandemic [1] . Over 25 million people have died and an estimated 33 million people are living with HIV [2 ] . In 2008, about 68% of people living with HIV were in sub-Saharan Africa with around 35% in eight countries alone [2 ] . HIV is the strongest risk factor for tuberculosis (TB) and an estimated 1.4 million people living with HIV developed TB causing 500 000 (23%) of total HIV-related deaths [3 ] . In 2005 and 2009, the G8 met in Scotland and Italy and committed to achieving universal access to HIV prevention, care and treatment by 2010 [2 ] . However, universal access remains a dream for millions of people and faces serious technical, economic and political challenges on a number of fronts [2 ] .
There has been an unprecedented investment in confronting the HIV pandemic -UNAIDS estimates US$13.8 billion in 2008 [4] . One of the major challenges facing us is how to not only sustain but also expand our response to the HIV epidemic in the face of the worst economic crisis since the 1930s. The significance and implications of the economic predicament are at times beyond comprehension. Over US$14.5 trillion, or 33%, of the value of the world's companies has been wiped out and US taxpayers alone will spend some US$9.7 trillion in bailout packages and plans [5] . The economic disaster is being felt worldwide and has already impacted investment in international and national public health.
Treatment and prevention gap
The imperative of providing life-saving antiretroviral therapy (ART) is now undisputed, and there is a pressing need for both increased investment and more efficient use of funding. By the end of year 2008, four million people were on highly active antiretroviral treatment (HAART) [2 ] . Despite this remarkable achievement, over five million needed treatment and in 2007 there were 2.7 million new infections [2 ] . Around 23 million
The human rights gap
The HIV epidemic highlights the serious lack of equity and human rights in our global public health response. The millions of people living with or at risk for HIV without access to HIV prevention, treatment and care can be interpreted a serious breach of the fundamental right to healthcare [6] . Coercion and other mandatory approaches to addressing the HIV epidemic have often had perverse negative outcomes. Engaging the community as a meaningful partner in the design and implementation of HIV programs is critical, particularly when the potential for stigma and human rights violations exist [7] . The existing stark economic disparities may exacerbate human rights issues and could further widen the increasingly divergent approaches to HIV prevention, care and treatment that are seen between rich and poor countries [8,9].
If it is broken then we should fix it. . .
Stopping the HIV epidemic remains elusive in most settings, and there is a need to re-examine our current approaches to stopping HIV. Combination prevention includes evidence-based interventions to address behavioral change, HAART, other biomedical strategies, and structural, social justice and human rights interventions [10, 11] . Of 27 randomized controlled trials of different biomedical interventions, including vaccines, microbicides and herpes suppression trials, 22 failed to show efficacy [12] [13] [14] . Positive trials include those for male circumcision and the sexually transmitted infection intervention trial in Mwanza, Tanzania, over a decade ago, of limited generalizability [14] . Users of the microbicide gel Pro 2000 had a nonstatistically significant 30% reduction in HIV incidence [15 ] . Pre-exposure prophylaxis (PrEP) is being assessed in 10 ongoing or planned international randomized controlled trials with results expected in 2010. Although the concept of PrEP is promising, it will undoubtedly be difficult to give drugs to HIV-uninfected persons when many people are dying from lack of access to HAART and may also face operational challenges around the need to repeat HIV testing to ensure that only those without HIV receive mono or dual therapy. A vaccine may provide an important future intervention [16 ] ; however, the overall situation has prompted many people to consider the potential prevention role of HAART [17, 18 ].
Scientific evidence for highly active antiretroviral treatment as prevention of HIV transmission
There is increasingly strong scientific evidence for HAART as prevention of HIV transmission. HIV transmission only occurs from people with HIV, the greatest risk factor for HIV transmission is the viral load and lowering the viral load is essential to interrupting transmission [1, 19] . Viral load predicts the risk of sexual transmission of HIV-1, which is rare among persons with levels of less than 1500 copies of HIV-1 RNA per milliliter [19, 20] . HAART dramatically lowers viral load and numerous observational studies have demonstrated its potential for prevention of HIV transmission [21, 22] . HAART with couples counseling in Uganda reduced transmission by 98% [22] . A 2009 meta-analysis [23] including 11 cohorts (5021 heterosexual couples) found zero risk of sexual transmission while on HAART for HIV-1 ribonucleic acid below 400 copies (upper confidence limit of 1.27 per 100 years). A recent randomized controlled study [ [34 ] found that patients with higher CD4 cell counts are being monitored too infrequently for the timely start of treatment and 25% of people die waiting for HAART. Although mortality rates at the higher CD4 cell count levels are lower, they are not zero, and may represent a significant impact on morbidity and mortality. In Zimbabwe, HIV mortality within 24 months postpartum in the absence of HAART was 54 times higher for those with CD4 cell counts less than 200 cells/ml, 5.4 times higher for counts 400-600, and the hazard remained elevated at 6.2 for counts greater than 600 [35 ] . North American cohort data showed a 94% increase in mortality for those who started treatment below CD4 cell count level of 500 when compared with those who started earlier [36 ] . Europe and North America cohorts including over 40 000 patients showed that starting treatment earlier reduced the risk of acquired immunodeficiency syndrome or death, with those starting before reaching 450 having the most benefit [30 ] . Other cohort studies [37, 39, 40 ,41] also suggest that starting earlier is better and the evidence increasingly points to the damaging effects of HIV even at higher CD4 cell count levels and the negative effects of letting CD4 cell counts drop too low. HAART has a significant role to play in preventing TB morbidity, transmission and mortality. In a randomized clinical trial [42 ] of 642 patients coinfected with HIV and TB in South Africa, starting HAART earlier during TB therapy reduced mortality rates by 56%. To prevent TB, we may have to intervene with HAART earlier before people living with HIV spend too long in the CD4 þ 'death zone' (<500 CD4 cells) for TB [32 ,33 ] . Recognizing this, WHO recently revised its guidelines to recommend ART for all with less than 350 CD4 cells [43 ] .
Trial data also point in the direction of an earlier start. The CIPRA HT 001 randomized clinical trial in Haiti was stopped by the Data Safety Monitoring Board because there were significantly fewer deaths and cases of TB in patients who started HAART earlier between 200 and 350 [44 ] . Survival curves show a 47% reduced progression or death in patients receiving immediate as opposed to deferred HAART in ACTG A 1564 [45 ] . The SMART trial and more recent work have suggested that starting earlier was superior and found that HIV may be associated with serious non-AIDSdefining events including cardiovascular, renal, and liver disease and non-AIDS malignancies [37, 38, 46 ].
The growing evidence suggests that HIV infection is likely a chronic inflammatory disease process, and provides additional rationale for an earlier start of HAART.
People living with HIV will eventually need HAART and the question is how long to wait until a person is immunocompromised enough to be eligible for treatment. Data from 30 international studies and 16 cohorts of untreated adults found relatively low CD4 cell count levels after HIV infection and a fairly rapid progression to CD4 cell count thresholds such as 500, 350 and 200 [47 ] . The time to eligibility was variable and, in some settings, only a few years after HIV infection [47 ] . From this perspective and assuming access to HAART, decisions whether to start at 200, 350 or 500 represent a few years earlier in the course of a much longer life span. Guidelines written for wealthier countries recommend starting people earlier before severe immunocompromised and use factors such as CD4 cell count decline, viral replication and discordant couple status as potential eligibility criteria even at higher CD4 cell counts [48] . The recently revised WHO guidelines also advise an earlier start [43 ] . Our challenge is to narrow the current treatment gulf that is largely based on available resources.
HIV counseling and testing
Regardless of when people should start HAART, universal access to prevention, care and treatment will require that millions of people with HIV learn their status. Despite considerable efforts to expand access to HIV testing, an estimated 80% of people living with HIV in sub-Saharan Africa do not know their status and 90% do not know their partners' status [2, 49] . In Kenya, a leader in improving access for HIV counseling and testing, 57% of people eligible for HAART by Kenyan CD4 cell count criteria have no idea that they have HIV [50 ] . However, 92% of those who knew their status and were eligible were on HAART [50 ] . HIV counseling and testing itself -particularly when it includes couples counseling -is a remarkably effective prevention intervention [22, [51] [52] [53] . Community-based efforts, including home-based couples counseling and testing, have considerable promise. In a district in Western Kenya, a private sector company with local nongovernmental organizations, Centers for Disease Control Kenya and the Ministry of Health were able to test 41 040 or 80% of the men and women between 15 and 49 years during a 7-day campaign [54] .
Modeling results
Models help us to better understand what we think we know and perhaps most importantly what we need to find out. Our model focused on a generalized HIV epidemic setting largely driven by heterosexual sex and used data from South Africa, Uganda, Malawi and elsewhere [18 ] . It builds on and extends, earlier analyses suggesting that rapid scale-up of conventional HAART approaches could significantly reduce mortality [55] and have a substantial impact on HIV incidence [56, 17] . The modeled universal voluntary HIV testing and immediate HAART strategy with combined prevention interventions resulted in a 95% reduction in HIV incidence in 10 years -a reduction from 15 000-20 000 per million population to 1000 per million. The prevalence becomes less than 1% by 2050 [18 ] .
. Current work includes an in-depth analysis of the economic impact of ART including human rights and campaign program elements and further modeling on the impact of ART on TB, which suggests a potential 60% reduction in incidence (unpublished data).
Modeling 'test and treat' for Washington, District of Columbia, concluded that the strategy could potentially decrease the number of new HIV infections there by as much as 26% over 10 years, and work in San Francisco suggests that incident infections could be reduced by 91% [57 ,58 ] . Other mathematical modeling studies [57 ,58 ,59 -61 ,62,63 ] have reviewed assumptions and examined 'test and treat' in other contexts, but a full discussion is beyond the scope of this article. Models are perhaps most useful when used to examine the potential impact of public health interventions and discuss programmatic targets for maximal impact. Models are sensitive to key assumptions, and when using more pessimistic parameters or a different context, the results are predictably less optimistic [59 -61 ,62] . One modeling group using hypothetical assumptions raised the spectre of widespread resistance [62] but actual data from programs providing HAART and population-based threshold studies [64] [65] [66] [67] 68 ] suggest that these claims may not reflect the actual situation. Resistance is of course a serious concern and WHO is working with stakeholders to monitor the situation through the WHO/HIVResNet HIVDR Laboratory Network, which currently includes over 30 laboratories covering the WHO's African, South-East Asia, Western Pacific and the Caribbean Regions [69, 70] . Although modeling is important, research studies and field trials will need to examine the key thresholds for program performance raised in the supporting information of the recent Lancet 
Conclusion
HIV is an infectious disease, and with the right interventions, it can be controlled and possibly even eliminated. Without a considerable effort to achieve universal access, millions of people will die before accessing HAART. HAART has considerable benefit both as treatment and in prevention and it is likely that it will be increasingly considered as a key element of combination prevention. . This important work is part of a body of work from this group demonstrating that the lower one's CD4 cell count, the higher risk for morbidity and mortality and in particular from TB. National HIV programs in resource-limited settings should be designed to minimize the time patients spend with CD4 cell counts less than 200 cells/ml both before and during ART. This important work is part of a body of work from this group demonstrating that the lower one's CD4 cell count, the higher risk for morbidity and mortality and in particular from TB. This group coined phrase 'death zone' for CD4 cell count less than 500 cells/ml level and concluded that TB prevention would be improved by ART policies that minimized the time patients spend with CD4 cell counts below a threshold of 500 cells/ml. Interesting work that illustrates that current policies recommending that people wait for further CD4 cell count decline may result in considerable mortality on the waiting list.
Hargrove JW, Humphrey JH. Mortality among HIV-positive postpartum women with high CD4 cell counts in Zimbabwe. AIDS 2010, 24:F11-F14. Major study that most people likely missed illustrates that in postpartum women living with HIV there is increased morbidity and mortality at all CD4 cell count levels and that risk never returns to baseline for those who are HIV negative. Directionally similar to other cohort studies that call into question waiting to start HAART until severely immunocompromised. Seminal look at North American cohorts that suggests that starting earlier before 350 and/or 500 cells/ml may have a significant mortality benefit. Among patients in the deferred-therapy group, there was an increase in the risk of death of 94%. The early initiation of ART before the CD4 þ cell count fell below two pre-specified thresholds significantly improved survival, as compared with deferred therapy. . Work focused on South Africa that suggests that earlier initiation of ART in South Africa will probably reduce morbidity and mortality, improve long-term survival and be cost-effective. While awaiting trial results, treatment guidelines should be liberalized to allow initiation at CD4 cell counts less than 350 cells/ml (earlier than was recommended at the time of the study). 
